BioSpace News Archive

Scientists closer to solving mystery of why lean people get fatty liver disease

Researchers from The Westmead Institute for Medical Research have discovered how fatty liver disease develops in lean people, aiding the development of potential treatments for these patients.

September 4, 2019
·
2 min read
Valo Therapeutics acquires PeptiENV technology from the University of Helsinki

Valo Therapeutics Limited announced that it has licensed proprietary PeptiENVTM technology from Helsinki University that enables the coating of enveloped viruses by neoantigen-peptides.

September 4, 2019
·
2 min read
Business

C4X Discovery forms Drug Discovery Advisory Network

World-renowned drug discovery experts to advance C4XD capabilities

September 4, 2019
·
3 min read
Business

Invest with an Option to Buy: Bristol-Myers Squibb Partners with Accelerator BioMotiv

Bristol-Myers will become a limited partner, investing in projects of mutual interest, with an option to buy the companies once there is a preclinical candidate.

September 4, 2019
·
3 min read
·
Mark Terry
BioCapital

Mitochondrial Calcium Transport: New Theory of Alzheimer’s

Researchers at Temple University Health System have shown that a type of energy malfunction, called mitochondrial calcium transport remodeling, is involved in the progression of Alzheimer’s disease.

September 4, 2019
·
2 min read
·
Mark Terry
Deals

Report: With No Settlement, Purdue Could File for Free-Fall Bankruptcy

Citing unnamed sources “familiar with the matter,” Reuters said that the company will have no choice but to file for bankruptcy should a settlement not be agreed upon.

September 4, 2019
·
3 min read
·
Alex Keown
Policy

Poll: Should Companies Be Allowed to Sue Other Companies to Prevent Generic Competition?

In the BioSpace poll, 55.17% of respondents said, Yes, companies should be allowed to sue competitors to prevent generic versions of their drugs, and 41.38% said no. A much smaller group, 3.45%, said they were unsure.

September 4, 2019
·
7 min read
Daiichi Sankyo Reports Non-Inferiority in Lixiana Clinical Trial for Atrial Fibrillation

The company indicates there was “a trend toward less bleeding with edoxaban, though, results did not show statistical superiority.”

September 4, 2019
·
2 min read
·
Mark Terry
Publication in Cancer Management and Research Underlines the Potential of Apogenix’ Asunercept for the Treatment of Other Malignancies Beyond Glioblastoma and MDS

Apogenix announced that a new publication in Cancer Management and Research[1] reviews asunercept as a promising treatment option for patients with other malignancies beyond glioblastoma and myelodysplastic syndromes.

September 4, 2019
·
4 min read
Deals

Dutch company receives €20 million for skin cancer diagnostic test

Benelux’ largest biotech investor Aat van Herk commits a €20 million investment in diagnostics company SkylineDx after reaching major milestones in 2018, financing SkylineDx’ market potential of over $1 billion annually based on their current progress in the melanoma field.

September 4, 2019
·
2 min read